Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James D Chambers

Showing results (1-10 of 92) with videos related to

Pageof 10
Sort By:
Pharmacoeconomics|May 27, 2014
Do changes in drug coverage policy point to an increased role for cost-effectiveness analysis in the USA?James D Chambers
Health Affairs (Project Hope)|June 10, 2015
Medicare's Interventions Coverage: The Authors ReplyJames D Chambers, Peter J Neumann
The New England Journal of Medicine|April 8, 2011
Listening to Provenge--what a costly cancer treatment says about future Medicare policyJames D Chambers, Peter J Neumann
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|May 17, 2011
What values do the public want their health care systems to use in evaluating technologies?Martin J Buxton, James D Chambers
The New England Journal of Medicine|November 2, 2012
Medicare's enduring struggle to define "reasonable and necessary" carePeter J Neumann, James D Chambers
Expert Review of Pharmacoeconomics & Outcomes Research|June 16, 2010
US healthcare reform: implications for health economics and outcomes researchJames D Chambers, Peter J Neumann
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 23, 2016
Thirty Years of Media Coverage on High Drug Prices in the United States--A Never-Ending Story or a Time for Change?Christine Leopold, James D Chambers, Anita K Wagner
Journal of Managed Care & Specialty Pharmacy|June 29, 2018
Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for HemophiliaTeja Thorat, Peter J Neumann, James D Chambers
Health Policy (Amsterdam, Netherlands)|December 16, 2014
Medicare's use of cost-effectiveness analysis for prevention (but not for treatment)James D Chambers, Michael J Cangelosi, Peter J Neumann
Health Affairs (Project Hope)|June 5, 2013
Medicare covers the majority of FDA-approved devices and Part B drugs, but restrictions and discrepancies remainJames D Chambers, Katherine E May, Peter J Neumann
Pageof 10

Showing results (1-10 of 92) with videos related to

Sort By:
Pageof 10
Pharmacoeconomics|May 27, 2014
Do changes in drug coverage policy point to an increased role for cost-effectiveness analysis in the USA?James D Chambers
Health Affairs (Project Hope)|June 10, 2015
Medicare's Interventions Coverage: The Authors ReplyJames D Chambers, Peter J Neumann
The New England Journal of Medicine|April 8, 2011
Listening to Provenge--what a costly cancer treatment says about future Medicare policyJames D Chambers, Peter J Neumann
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|May 17, 2011
What values do the public want their health care systems to use in evaluating technologies?Martin J Buxton, James D Chambers
The New England Journal of Medicine|November 2, 2012
Medicare's enduring struggle to define "reasonable and necessary" carePeter J Neumann, James D Chambers
Expert Review of Pharmacoeconomics & Outcomes Research|June 16, 2010
US healthcare reform: implications for health economics and outcomes researchJames D Chambers, Peter J Neumann
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 23, 2016
Thirty Years of Media Coverage on High Drug Prices in the United States--A Never-Ending Story or a Time for Change?Christine Leopold, James D Chambers, Anita K Wagner
Journal of Managed Care & Specialty Pharmacy|June 29, 2018
Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for HemophiliaTeja Thorat, Peter J Neumann, James D Chambers
Health Policy (Amsterdam, Netherlands)|December 16, 2014
Medicare's use of cost-effectiveness analysis for prevention (but not for treatment)James D Chambers, Michael J Cangelosi, Peter J Neumann
Health Affairs (Project Hope)|June 5, 2013
Medicare covers the majority of FDA-approved devices and Part B drugs, but restrictions and discrepancies remainJames D Chambers, Katherine E May, Peter J Neumann
Pageof 10